Ventripoint Doubles the Size of Private Placement Due to Strong Investor Demand

Core Viewpoint - Ventripoint Diagnostics Ltd. is responding to significant investor interest by doubling its non-brokered private placement from $500,000 to $1,000,000, pending approval from the TSX Venture Exchange [1]. Group 1: Offering Details - Each unit in the offering will consist of one common share and one common share purchase warrant [2]. - Each warrant allows the holder to purchase one common share at a price of $0.13 for a period of 24 months from the closing of the offering, with the potential for an accelerated expiry if the common shares trade at $0.26 or above for 10 consecutive days [3]. - The corporation may pay a cash finder's fee and issue finder's warrants of up to 8% of the gross proceeds, with each finder's warrant also exercisable into one common share at the same price of CDN$0.13 for 24 months [4]. Group 2: Use of Proceeds - The proceeds from the offering will be utilized to support critical commercialization activities, manufacturing scale-up, continued regulatory submissions, and operational requirements [5]. Group 3: Company Overview - Ventripoint has established itself as a leader in AI-powered echocardiography, with its VMS+ products providing accurate volumetric cardiac measurements comparable to MRI, developed over a decade [9]. - The technology is designed to be an affordable alternative, enhancing cardiologists' confidence in patient management and is compatible with all ultrasound systems from various vendors, supported by regulatory approvals in the U.S., Europe, and Canada [9].